Stress protection method for surgical treatment of patients with head and neck cancer

Introduction. The surgical stage of treatment is the most important component of the combined method of treatment in cancer patients. However, it is associated with the development of a number of complications caused by stress. In this regard, the modern concept of an anesthesiological manual should also be aimed at protecting the body from surgical stress, which requires the search and development of new gentle methods of anesthesia.

Aim. To provide an overview of modern stress protection methods in anesthesia and consider the role of dalargin with carbohydrate loading as a component of stress protection in oncological surgery.

Materials and methods. Using the electronic resources of the PubMed and eLibrary search engines, a literary review of 147 scientific papers over the past 30 years has been conducted, which contain an evidence-based experimental and clinical base on the use of dalargin in medical practice.

Results. A systematic review of stress protection methods in anesthesiology is presented. The role of dalargin in anesthesiological practice during surgical treatment in cancer patients, including when performing delayed reconstructions, is shown.

Conclusion. The use of dalargin in combination with carbohydrate loading in cancer patients is justified and requires further detailed study. The ability to stimulate endogenous opioid receptors and modulate pain perception, its organoprotective and anti-inflammatory properties, as well as a favorable safety profile make dalargin a valuable addition to the tools for anesthesia in oncology.

1. Pfister D.G., Spencer S., Adelstein D. et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18(7):873–98. DOI: 10.6004/jnccn.2020.0031

2. Gorobets E.S., Sviridova S.P. Problems and achievements of anesthesiology and resuscitation in modern oncosurgery. Anesteziologiya i reanimatologiya = Anesthesiology and Resuscitation 2002;5:29–33. (In Russ.).

3. Stranix J.T., Stern C.S., Rensberger M. et al. A Virtual surgical planning algorithm for delayed maxillomandibular reconstruction. Plast Reconstr Surg 2019;143(4):1197–206. DOI: 10.1097/PRS.0000000000005452

4. Won H.R., An J.Y., Lee J.J. et al. The effectiveness of an enhanced recovery after surgery protocol in head and neck cancer surgery with free-flap reconstruction. Ann Surg Treat Res 2019;97(5):239–44. DOI: 10.4174/astr.2019.97.5.239

5. Dort J.C., Farwell D.G., Findlay M. et al. Optimal perioperative care in major head and neck cancer surgery with free flap reconstruction: a consensus review and recommendations from the enhanced recovery after surgery society. JAMA Otolaryngol Head Neck Surg 2017;143(3):292–303. DOI: 10.1001/jamaoto.2016.2981

6. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 2003;17(Suppl. 1):S27–36. DOI: 10.1016/s0889-1591(02)00063-6

7. Gupta G.P., Massagué J. Cancer metastasis: building a framework. Cell 2006;127(4):679–95. DOI: 10.1016/j.cell.2006.11.001

8. Ovechkin A.M. Anesthesia and analgesia in oncology: what determines the choice? Regionarnaya anesteziya i lechenie ostroj boli = Regional anesthesia and acute pain treatment 2012;6(2): 5–15. (In Russ.).

9. Tan H.K., Giger R., Auperin A. et al. Salvage surgery after concomitant chemoradiation in head and neck squamous cell carcinomas – stratification for postsalvage survival. Head Neck 2010;32(2):139–47. DOI: 10.1002/hed.21159

10. Kim H.S., Chung C.H., Chang Y.J. Free-flap reconstruction in recurrent head and neck cancer: A retrospective review of 124 cases. Arch Craniofac Surg 2020;21(1):27–34. DOI: 10.7181/acfs.2019.00738

11. Yeager M.P., Rosenkranz K.M. Cancer recurrence after surgery: a role for regional anesthesia? Reg Anesth Pain Med 2010;35(6):483–4. DOI: 10.1097/aap.0b013e3181fa11a9

12. Kulbakin D.E., Choinzonov E.L., Mukhamedov M.R. et al. Postoperative complications of reconstructive and reconstructive operations in patients with head and neck tumors. Sibirskij onkologicheskij zhurnal = Siberian Journal of Oncology 2021;20(1):53–61. (In Russ.). DOI: 10.21294/1814-4861-2021-20-1-53-61

13. Sacerdote P., Bianchi M., Gaspani L. et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 2000;90(6):1411–4. DOI: 10.1097/00000539-200006000-00028

14. Page G.G., Blakely W.P., Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001;90(1–2):191–9. DOI: 10.1016/s0304-3959(00)00403-6

15. Snyder G.L., Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010;105(2):106–15. DOI: 10.1093/bja/aeq164

16. Goldfarb Y., Ben-Eliyahu S. Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches. Breast Dis 2006–2007;26:99–114. DOI: 10.3233/bd-2007-26109

17. Eskander A., Kang S., Tweel B. et al. Predictors of complications in patients receiving head and neck free flap reconstructive procedures. Otolaryngol Head Neck Surg 2018;158(5):839–47. DOI: 10.1177/0194599818757949

18. Aahlin E.K., Tranø G., Johns N. et al. Risk factors, complications and survival after upper abdominal surgery: a prospective cohort study. BMC Surg 2015;15:83. DOI: 10.1186/s12893-015-0069-2

19. Marret E., Kurdi O., Zufferey P. et al. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology 2005;102(6):1249–60. DOI: 10.1097/00000542-200506000-00027

20. Singleton P.A., Mirzapoiazova T., Hasina R. et al. Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth 2014;113(Suppl. 1):i103–8. DOI: 10.1093/bja/aeu165

21. Lennon F.E., Moss J., Singleton P.A., Riou B. The μ-opioid receptor in cancer progression: is there a direct effect? Anesthesiology 2012;116(4):940–5. DOI: 10.1097/ALN.0b013e31824b9512

22. Jarzyna D., Jungquist C.R., Pasero C. et al. American Society for Pain Management Nursing guidelines on monitoring for opioidinduced sedation and respiratory depression. Pain Manag Nurs 2011;12(3):118–45.e10. DOI: 10.1016/j.pmn.2011.06.008

23. Karelov A.E. Modern ideas about the mechanisms of pain. Anesteziologiya i reanimatologiya = Anesthesiology and Resuscitation 2020;(6):88–95. (In Russ.).

24. Apfelbaum J.L., Chen C., Mehta S.S., Gan T.J. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg 2003;97(2):534–40. DOI: 10.1213/01.ANE.0000068822.10113.9E

25. Sultana A., Torres D., Schumann R. Special indications for Opioid Free Anaesthesia and Analgesia, patient and procedure related: including obesity, sleep apnoea, chronic obstructive pulmonary disease, complex regional pain syndromes, opioid addiction and cancer surgery. Best Pract Res Clin Anaesthesiol 2017;31(4): 547–60. DOI: 10.1016/j.bpa.2017.11.002

26. Coyne K.S., LoCasale R.J., Datto C.J. et al. The burden of opioidinduced constipation: discordance between patient and health care provider reports. J Manag Care Spec Pharm 2016;22(3):236–45.

27. Shavit Y., Ben-Eliyahu S., Zeidel A. et al. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation 2004;11(4):255–60. DOI: 10.1159/000078444

28. Hutton M., Brull R., Macfarlane A.J.R. Regional anaesthesia and outcomes. BJA Educ 2018;18(2):52–6. DOI: 10.1016/j.bjae.2017.10.002

29. Brull R., McCartney C.J., Chan V.W. et al. Neurological complications after regional anesthesia: contemporary estimates of risk. Anesth Analg 2007;104(4):965–74. DOI: 10.1213/01.ane.0000258740.17193.ec

30. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 2003;21(1):21–32. DOI: 10.1023/a:1022951824806

31. Farooqui M., Li Y., Rogers T. et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007;97(11):1523–31. DOI: 10.1038/sj.bjc.6604057

32. Leahy K.M., Ornberg R.L., Wang Y. et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62(3):625–31.

33. Coxib and traditional NSAID Trialists’ (CNT) Collaboration; Bhala N., Emberson J., Merhi A. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382(9894):769–79. DOI: 10.1016/S0140-6736(13)60900-9

34. Zhang C., Xie C., Lu Y. Local Anesthetic Lidocaine and Cancer: Insight Into Tumor Progression and Recurrence. Front Oncol 2021;11:669746. DOI: 10.3389/fonc.2021.669746

35. Sakaguchi M., Kuroda Y., Hirose M. The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. Anesth Analg 2006;102(4):1103–7. DOI: 10.1213/01.ane.0000198330.84341.35

36. Xing W., Chen D.T., Pan J.H. et al. Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. Anesthesiology 2017;126(5):868–81. DOI: 10.1097/ALN.0000000000001528

37. Nygren J. The metabolic effects of fasting and surgery. Best Pract Res Clin Anaesthesiol 2006;20(3):429–38. DOI: 10.1016/j.bpa.2006.02.004

38. Lobo D.N., Gianotti L., Adiamah A. et al. Perioperative nutrition: Recommendations from the ESPEN expert group. Clin Nutr 2020;39(11):3211–27. DOI: 10.1016/j.clnu.2020.03.038

39. Gustafsson U.O., Scott M.J., Hubner M. et al. Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018. World J Surg 2019;43(3):659–95. DOI: 10.1007/s00268-018-4844-y

40. Belousova E.A., Bulgakov S.A. Drugs – ligands of opiate receptors and their use in gastroenterology. Farmateka = Pharmateca 2011;2:26–31. (In Russ.).

41. Garmaeva D.V. Effect of leu-enkephalin analogue on the myeloid compartment of the blood system in hypothyroid white rats under stress conditions. Bull Exp Biol Med 2022;173(1):1–4. DOI: 10.1007/s10517-022-05479-2

42. Migone C., Mattii L., Giannasi M. et al. Nanoparticles based on quaternary ammonium chitosan-methyl-β-cyclodextrin Conjugate for the Neuropeptide Dalargin Delivery to the central nervous system: an in vitro study. Pharmaceutics 2020;13(1):5. DOI: 10.3390/pharmaceutics13010005

43. Bebyakova N.A., Levitsky S.N., Shabalina I.A. The effect of structural modification of the dalargin molecule on the vasoactive effect of the peptide under acute stress. Fundamental’nye issleldovaniya = Fundamental Research 2011;12:704–7. (In Russ.).

44. Shloznikov B.M., Donich S.G., Grebenchikov O.A. Study of the antinociceptive properties of dalargin as a means of anesthetic protection. Byulleten’ eksperimental’noj biologii i mediciny = Bulletin of Experimental Biology and Medicine 1990;3:272–4. (In Russ.).

45. Chesnokov D.N., Churlyaev Yu.A., Denisov E.N. et al. The use of dalargin for intraoperative protection of the brain during neurosurgical interventions. Anesteziologiya i reanimatologiya = Anesthesiology and Resuscitation 2000;6:21–2. (In Russ.).

46. Likhvantsev V.V., Grebenchikov O.A., Plotnikov E.Yu. et al. Mechanisms of pharmacological preconditioning of the brain and comparative efficacy of glycogen synthetase-kinase-3 beta inhibitors of direct and indirect action (experimental study). Общая реаниматология = General Resuscitation 2012;8(6):37–42. (In Russ.).

47. Sazonova E.N., Lebed’ko O.A., Pinaeva O.G. et al. Role of amino acid arginine and nitric oxide in mechanisms of cytoprotective effect of non-opiate leu-enkephalin analogue in vitro. Bull Exp Biol Med 2021;172(2):270–5. DOI: 10.1007/s10517-021-05374-2

48. Grebenchikov O.A., Shabanov A.K., Kosov A.A. et al. Synthetic leu-enkefalin analogue prevents activation of neutrophils induced by a bacterial component. Al’manah klinicheskoj mediciny = Almanac of Clinical Medicine 2019;47(3):228–35. (In Russ.). DOI: 10.18786/2072-0505-2019-47-026

49. Likhvantsev V.V. Intraoperative organoprotection as a necessary component of balanced anesthesia. Moscow, 1990. (In Russ.).

50. Slepushkin V.D. The use of dalargin in anesthesiology and intensive care. Vestnik intensivnoj terapii = Bulletin of Intensive Care 1996;1:7–8. (In Russ.).

51. Bulgakov S.A. Dalargin in gastroenterology. Moscow, 2008. 49 p. (In Russ.).

52. Shloznikov B.M., Korotkina R.N., Babkina N.V. et al. The effect of dalargin on some indicators of lipid peroxidation in the liver. Byulleten’ eksperimental’noj biologii i mediciny = Bulletin of Experimental Biology and Medicine 1990;110(12):609–10. (In Russ.).

53. Grebenchikov O.A., Cherpakov R.A., Likhvantsev V.V. et al. New directions in the prevention and treatment of acute renal failure. Vestnik anesteziologii i reanimatologii = Bulletin of Anesthesiology and Resuscitation 2014;11(4):43–51. (In Russ.).

54. Zabolotskikh I.B., Malyshev Yu.P. Optimization of anesthesiological support for complex long-term operations in abdominal surgery: a manual for doctors. Krasnodar, 1996. 25 p. (In Russ.).

55. Slepushkin V.D., Nikolaev A.A. The use of dalargin in domestic oncology. Palliativnaya medicina i reabilitaciya = Palliative Medicine and Rehabilitation 2004;1:5–10. (In Russ.).

56. Horvat S., Mlinarić-Majerski K., Glavas-Obrovac L. et al. Tumorcell-targeted methionine-enkephalin analogues containing unnatural amino acids: design, synthesis, and in vitro antitumor activity. J Med Chem 2006;49(11):3136–42. DOI: 10.1021/jm051026

57. Vasilyev A.V., Bukharova T.B., Volkov A.V. et al. Effects of dalarginum on proliferation of multipotent mesenchymal stromal cells, dermal fibroblasts, and human osteosarcoma cells in vitro. Geny i kletki = Genes and Cells 2014;9(4):76–80. (In Russ.).

58. Grebenchikov O.A., Ovezov A.M., Skripkin Yu.V. et al. A synthetic analogue of ley-enkephalin prevents the development of endothelial dysfunction in vitro. Общая реаниматология = General resuscitation 2018;14(2):60–8. (In Russ.).

59. Likhvantsev V.V., Grebenchikov O.A., Shaposhnikov A.A. et al. Pharmacological preconditioning: role of opioid peptides. Obshchaya reanimatologiya = General Reanimatology 2012;8(3): 5–15. (In Russ.). DOI: 10.15360/1813-9779-2012-3-51